Pan Cancer T, a biotechnology spin-out from Erasmus MC, announced the closing of an extended seed investment round. All of their current shareholders participated, with Thuja Capital joining as a new investor. Pan Cancer T dedicates itself to the discovery and development of novel TCR-T therapies against solid tumors, and will use the proceeds, combined with the initial seed capital financing from earlier this year to continue its research.
